Merck KGaA Names Heads of North American and China Biopharmaceutical BusinessesBy
Merck KGaA, has appointed two new heads for its biopharmaceutical business in North America and China. Gary Zieziula will lead the biopharmaceutical business of Merck KGaA in North America, and Marc Horn will take the helm of the company's biopharmaceutical business in China.
Gary Zieziula has been appointed president and managing director of the biopharmaceutical business in the US and Canada, based in Rockland, Massachusetts, with immediate effect. Zieziula's predecessor, Paris Panayiotopoulos, accepted a new position outside of Merck KGaA athe end of last year.
In his role, he will be responsible for all areas of the company's business including driving overall strategic direction and maximizing growth across the region. Zieziula joined Merck KGaA in 2014 as chief commercial officer in the US, having spent more than 30 years in the pharmaceutical industry, including senior level positions at Merck & Co. Bristol Myers-Squibb, Roche and Amag Pharmaceuticals.
Marc Horn will head the biopharmaceutical business of Merck KGaA in China as of April 1, 2016, as a managing director based in Beijing. He is currently the regional chief financial officer (CFO), responsible for Eastern Asia, comprising China, Hong Kong, Japan, South Korea and Taiwan, for the three divisional business sectors: Healthcare, Life Science, and Performance Materials. Allan Gabor, Mark Horn's predecessor, has been promoted to president of the AsianPacific region for the biopharmaceutical business of Merck KGaA. In his new position, Horn will report to Gabor.
Horn has more than 16 years of management experience in finance in the pharmaceuticals and chemicals industry, including positions at Bayer and Lanxess in Germany, China and Singapore.
Source: Merck KGaA